What are the delayed-type cutaneous reactions associated with adalimumab and how should they be managed?

Delayed Cutaneous Reactions to Adalimumab

Delayed cutaneous reactions to adalimumab range from benign injection site reactions (occurring in 15% of patients) to rare severe cutaneous adverse reactions, and management depends on severity grading with most mild-to-moderate reactions requiring only symptomatic treatment while severe reactions mandate permanent drug discontinuation. 1

Types of Delayed Cutaneous Reactions

Common Benign Reactions

• Injection site reactions occur in 15% of adalimumab-treated patients compared to 9% receiving placebo, typically resolving within the first 2 months without requiring discontinuation 1
• Non-injection site rash is commonly reported and generally self-limiting 1
• Eruptive seborrheic keratoses have been documented as a rare delayed reaction, presenting as pruritic, burning papular erythematous rash that resolved within 3 months of drug discontinuation 2

Immunologic Mechanisms

• Type I hypersensitivity (IgE-mediated) can cause worsening injection site reactions, demonstrated by positive skin testing and histamine release assays in affected patients 3
• Type IV T-cell mediated reactions represent delayed-type hypersensitivity requiring stable drug-protein conjugate formation 4
• Delayed cutaneous hypersensitivity reactions in COVID-19 patients showed median onset of 166.5 days (IQR: 18-889.5 days) with adalimumab 5

Severe Cutaneous Adverse Reactions (SCARs)

• Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) are rare but potentially life-threatening 6
• These severe reactions are not amenable to desensitization and mandate permanent drug avoidance 6
• Presenting symptoms include fever, widespread rash, skin pain, skin sloughing, facial or upper-extremity edema, pustules, blisters, or erosions 6

Management Algorithm by Severity Grade

Grade 1 (Mild) Reactions

• Continue adalimumab without interruption 6
• Provide symptomatic treatment with oral antihistamines (diphenhydramine 25-50 mg or second-generation antihistamine) 7
• Topical corticosteroids for localized reactions 6
• Corticosteroids are not usually indicated for grade 1 reactions 6

Grade 2 (Moderate) Reactions

• Hold adalimumab temporarily during treatment 6
• Start oral prednisone 0.5-1 mg/kg/day if patient can take oral medication 6
• If IV required, use methylprednisolone 0.5-1 mg/kg/day IV 6
• If no improvement in 2-3 days, increase corticosteroid dose to 2 mg/kg/day 6
• Once improved to ≤grade 1, initiate 4-6 week steroid taper 6
• Resume adalimumab only after resolution to ≤grade 1 6

Grade 3-4 (Severe) Reactions

• Permanently discontinue adalimumab immediately 6
• Stop infusion and switch IV line to normal saline 7
• Administer aggressive symptomatic treatment with antihistamines (diphenhydramine 25-50 mg IV) and corticosteroids (methylprednisolone 100 mg IV) 8
• Do not attempt rechallenge or desensitization for severe reactions including bronchospasm, severe hypotension, angioedema, or anaphylaxis 7
• Hospitalization may be required for management of infection risk, symptoms, wound care 6

SCARs (SJS/TEN, DRESS, AGEP)

• Immediate and permanent discontinuation is mandatory 6
• Immediate specialist dermatology referral 6
• These reactions are associated with long-lasting memory T-cell responses and are not amenable to desensitization 6
• Delayed-type intradermal testing (dIDT) may be useful for certain cutaneous adverse reactions but should be avoided in SJS/TEN where sensitivity is low 6

Diagnostic Evaluation

Clinical Assessment

• Categorize the specific type of cutaneous reaction beyond non-specific maculopapular eruptions, as management algorithms reflect approaches to idiopathic skin disorders 6
• Dermatologic assessments are warranted in patients with known history of immune-related skin disorders such as psoriasis, bullous pemphigoid, or lupus 6
• Assess for systemic symptoms: fever, mucosal involvement, facial edema, skin pain, or sloughing 6

Timing Considerations

• Onset typically occurs within days to weeks but can be delayed, appearing after several months of treatment 6
• Median onset for delayed hypersensitivity reactions can be as late as 166.5 days 5
• Most injection site reactions resolve within the first 2 months of therapy 1

Laboratory and Testing

• Skin biopsy should be obtained when diagnosis is uncertain to differentiate between inflammatory dermatoses, bullous dermatoses, and SCARs 6
• Patch testing can provide additional diagnostic benefits for delayed-type reactions 4
• In vitro cellular incubation tests should be reserved for specialized laboratories 4

Critical Pitfalls to Avoid

• Never restart at full dose after a reaction—always resume at lower intensity after complete symptom resolution 7
• Do not delay treatment of severe reactions, as they can rapidly progress 8
• Do not attempt desensitization for SCARs (SJS/TEN, DRESS, AGEP), as these are T-cell mediated with long-lasting memory responses 6
• Do not minimize the significance of grade 2 reactions—these require temporary drug hold and systemic corticosteroids 6
• Do not use corticosteroids alone without antihistamines for acute reactions, as combination therapy provides optimal symptom control 8
• Monitor for autoimmune complications including lupus-like reactions (15 cases reported) and vasculitis (5 cases reported) 1

Special Monitoring Considerations

• Patients should be educated to report fever or signs of infection immediately, as adalimumab increases serious infection risk 1
• Dermatology consultation should be obtained early for persistent or worsening cutaneous reactions to guide evidence-based specialty care 6
• Longitudinal monitoring is essential as onset can be delayed even after several months of treatment 6